Wells Fargo analyst Mohit Bansal reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and maintains $1200 price target.
Wells Fargo Reiterates Overweight on Regeneron Pharmaceuticals, Maintains $1200 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.